Hoth Therapeutics Inc. Announces the Addition of Dr. Richard D Granstein, M.D. to the Company's Technology Advisory Board

NEW YORK, Oct. 16, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or  the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Richard D. Granstein, M.D., to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

Robb Knie, CEO of Hoth stated, "We are continuing to leverage the investment made by Spherix Incorporated (NASDAQ: SPEX) to expand and grow the BioLexa Platform by adding Dr. Granstein to our Technology Advisory Board.  Dr. Granstein is one of the nation's most esteemed dermatologist and the current Chairman of the Department of Dermatology at Weill Cornell Medical Center.  His extensive and prestigious background studying skin disorders will be invaluable to the Company in our attempt to bring relief to the approximately 32 million Americans suffering from eczema."

Richard D. Granstein, M.D. is the George W. Hambrick, Jr. Professor and Chairman of the Department of Dermatology. Dr. Granstein obtained his undergraduate education at the Massachusetts Institute of Technology and his medical education at the UCLA School of Medicine. After completing his internship in 1979, he trained in dermatology at the Massachusetts General Hospital. As a Research Fellow, Dr. Granstein studied immunology and tumor biology at the National Cancer Institute-Frederick Cancer Research Facility and at Harvard Medical School. Dr. Granstein joined the faculty of the Department of Dermatology at Harvard Medical School and the Massachusetts General Hospital in 1984. In 1995 he left Harvard to become Chairman of the Department of Dermatology at the Weill Medical College of Cornell University and Dermatologist-in-Chief at the NewYork-Presbyterian/Weill Cornell Medical Center.

Dr. Granstein's research interests center on the regulation of immunity within the skin and the relationship of the skin's immune system to the development of skin cancers. He also has a special research interest in the regulation of the immune system by stress and the nervous system. He was the first to demonstrate that certain immune cells within the skin are capable of initiating an immune response against a malignant tumor and that immune cells within the epidermis (the upper layer of the skin) have an anatomic relationship with nerves and can be regulated by proteins produced by those nerves. His clinical interests include autoimmune disorders of the skin, skin cancer, and psoriasis.

About Hoth Therapeutics Incorporated

Hoth Therapeutics Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. We are a small company with limited financial resources and our scientific background and abilities to implement a commercialization strategy is subject to ever-changing market conditions and rapidly-advancing technologies over which we have no control. While we believe that these forward-looking statements are reasonable, market conditions and competition in the marketplace is ever-changing and we have no control over these influences. As a result, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC") including, but not limited to, the Risk Factors relating to the Company's patent business and other aspects of the Company's business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Hoth Therapeutics, Inc. 
[email protected] 
646-722-2899 
www.hoththerapeutics.com

SOURCE Hoth Therapeutics Inc.

Related Links

http://www.hoththerapeutics.com